- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00449358
Checking Wether the m-ALA Cream Could Mark Correctly the Borders of BCC's Tumors
April 14, 2013 updated by: Assuta Hospital Systems
Correlation Between Mohs Surgery and Microscopic Fluorescence Photometry in Determination of Histological Borders in Basal Cell Carcinoma .
Correlation between Mohs surgery and microscopic fluorescence photometry in determination of histological borders in Basal Cell Carcinoma .
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Background: Basal Cell Carcinoma (BCC) is the most common form of nonmelanoma skin cancer worldwide.
BCCs are slow-growing, locally invasive tumors that rarely metastasize but can cause extensive morbidity through local tissue destruction.
Recurrence is often the consequence of incomplete removal of the cancer tissue.
Mohs' micrographic surgery is considered the most effective treatment modality for BCC with a recurrence rate of less than 5 %, however, the technique requires specialized training and is labor-intensive and costly.
Fluorescence imaging by topical application of a tumor-localizing agent such as methyl 5-aminolevulinic acid (MAL), resulting in buildup of photosensitizing porphyrin IX (PpIX) that can be visualized by Woods' light fluorescence, might serve as a quick and simple "bed-side" technique for demarcation of BCC tumor borders prior to surgical excision Objective: To test the reliability of MAL-induced porphyrin fluorescence tumor demarcation by comparison with the tumor borders determined by Mohs' surgery Methods: Twenty eight patients with facial BCCs (17 nodular, 3 superficial, 1 morphea type, 3 ulcerated and 4 recurrent tumors) scheduled for Mohs' surgery were recruited for the study.
The night before the surgical procedure, crusts were gently removed and an approximately 1 mm thick layer of a cream containing 16 % MAL (MetvixR) was applied to the tumor area as well as to the surrounding skin and covered by a transparent occlusive dressing.
The following morning (10-17 hours after MetvixR application), the dressing was removed, and the lesion size was determined with a caliber by measuring the largest perpendicular diameters under natural (clinical size) and Woods' (fluorescence size) illumination.
The patients then underwent the scheduled Mohs' surgical procedure, and the tumor size (Mohs' size) was determined when reaching the tumor free margins.
Study Type
Interventional
Enrollment
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tel-aviv, Israel
- Assuta hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A- bove 18 years
Exclusion Criteria:
- Childern
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
comparing the tumor area measured with the PDD thechnique and the actual tumor size found at the end of the Mohs surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Enk David, m.d, phd, Hadassah ein-karem university hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2006
Study Completion (Anticipated)
April 1, 2013
Study Registration Dates
First Submitted
March 19, 2007
First Submitted That Met QC Criteria
March 19, 2007
First Posted (Estimate)
March 20, 2007
Study Record Updates
Last Update Posted (Estimate)
April 16, 2013
Last Update Submitted That Met QC Criteria
April 14, 2013
Last Verified
January 1, 2006
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands
-
Kavita SarinNational Institutes of Health (NIH); Medivir; American Skin AssociationCompletedSkin Basal Cell CarcinomaUnited States
Clinical Trials on apply methyl-ALA cream
-
Joint Authority for Päijät-Häme Social and Health...Tampere University; University of JyvaskylaActive, not recruitingCarcinoma, Basal Cell | Neoplasms, Basal Cell | Photosensitizing Agents | PhotochemotherapyFinland
-
Merete HaedersdalCompleted
-
Centre Hospitalier Universitaire de NiceUnknownLamellar IchthyosisFrance
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedPain | Recurrent Skin Cancer | Basal Cell Carcinoma of the SkinUnited States
-
Biofrontera Bioscience GmbHAccovion GmbHCompleted
-
Biofrontera Bioscience GmbHAccovion GmbHCompletedBasal Cell Carcinoma (BCC)Germany
-
Galderma R&DCompletedActinic KeratosesGermany
-
Galderma R&DCompletedActinic KeratosisUnited States
-
Galderma R&DCompletedSuperficial Basal Cell CarcinomaFinland, Austria, Belgium, France, Italy, Sweden, United Kingdom
-
Joint Authority for Päijät-Häme Social and Health...Helsinki University Central HospitalCompletedActinic KeratosesFinland